Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Scholar Rock Holding CorporationNASDAQ: SRRK

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin at -18607.2%

Operating margin was -18607.2% in Q3 FY2026. On a trailing-twelve-month basis it was -71732.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-18607.2%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2026
-71732.3%— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2022
-404.8%
Year-over-year change
+285.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 operating margin of -71732.3% is the lowest of the 9 companies compared; the peer median is -159.2%.
SRRK Competitors Peer median
Operating Margin for SRRK and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202611.5% -29.2 pp+113.5 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-1.9% +3.4 pp+27.5 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-58.9% -30.2 pp+29.4 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-76.2% +202.2 pp+546.3 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-242.3% +497.7 pp+281.0 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-577.5% -597.5 pp+830.1 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-670.3% -700.2 pp—
XENEXenon Pharmaceuticals Inc.FY2025-4974.3% —-3605.4 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-71732.3% ——
EWTXEdgewise Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
Peer median (excluding SRRK) -159.2%-29.2 pp+113.5 pp

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.82M33.19M000
Cost of Revenue108.47M123.04M2.84M1.94M208.44M
Gross Profit(89.65M)(89.85M)(2.84M)(1.94M)(208.44M)
Gross Margin-476.5%-270.7%———
Research & Development108.47M124.44M119.06M182.61M208.44M
Selling, General & Admin40.27M42.62M49.4M67.5M176.21M
Operating Expenses40.27M44.52M168.45M250.12M176.21M
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
EBITDA(129.17M)(129.48M)(162.95M)(237.52M)(369.39M)
EBITDA Margin-686.5%-390.1%———
Operating Income(129.92M)(134.37M)(171.3M)(252.05M)(384.65M)
Operating Margin-690.5%-404.8%———
Interest Income00012.68M13.9M
Interest Expense0006.84M6.89M
Other Income / Expenses(1.88M)(132K)5.51M5.76M6.71M
Income Before Tax(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Pre-Tax Margin-700.5%-405.2%———
Income Tax Expense00000
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Net Margin-700.5%-405.2%———
EPS (Basic)(3.59)(2.21)(1.99)(2.47)(3.29)
EPS (Diluted)(3.59)(2.21)(1.99)(2.47)(3.29)
Weighted Avg Shares36.71M59.61M75.98M99.84M114.7M
Weighted Avg Shares (Diluted)36.71M59.61M75.98M99.84M114.7M

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.